Pertuzumab
Cat.No:IP7020 Solarbio
CAS:380610-27-5
Purity:≥98%
Appearance:Liquid
Qty:
Size:
{{cart_num}}
My CartCAS:380610-27-5
Purity:≥98%
Appearance:Liquid
Qty:
Size:
CAS | 380610-27-5 |
Name | Pertuzumab |
Purity | ≥98% |
Appearance | Liquid |
Target Point | HER2 |
Passage | Angiogenesis; Protein Tyrosine Kinase/RTK |
Background | Pertuzumab is a monoclonal antibody that inhibits HER2 dimerization and disrupts HER2s ability to bind to other members of HER family. |
Biological Activity | Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.[1-2] |
Data Literature Source | [1]. Nahta R, et al. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survivalof breast cancer cells. Cancer Res. 2004 Apr 1;64(7):2343-6. [2]. Scheuer W, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009 Dec 15;69(24):9330-6. |
Unit | Bottle |
Specification | 1mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.